Genmab — Februar 2020
-
ofatumumab may represent an additional option to treat post-transplant FSGS relapse in patients who respond poorly to rituximab. Our experience suggests that its effectiveness could be related to prolonged depletion of potentially pathogenic switched memory B cells. Pediatric Nephrology volume 35, pages341–345(2020)
-
Er der et nyt marked for Ofa i CLL?
-
Jeg troede at Ofa var en død sild i cancer?
-
-
God morgen.
-
Abwehrkampf gegen Leukämie - https://www.welt.de/print/die_welt/article205575129/Abwehrkampf-gegen-Leukaemie.html
-
Maintenance Therapy and Relapse/Refractory Treatment https://www.ajmc.com/post-conference-perspectives/ash2019-myeloma/maintenance-therapy-and-relapserefractory-treatment
-
Ireland - Improving access to cancer drugs - https://www.irishtimes.com/opinion/letters/improving-access-to-cancer-drugs-1.4160471
-
Thx E L. Results from Janssen's B-ALL and T-ALL study should be out late 2020 https://www.clinicaltrials.gov/ct2/show/NCT03384654?term=all+daratumumab&draw=2&rank=2#contacts
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind